Novartis AG ADR (NVS)vsVanda Pharmaceuticals Inc (VNDA)
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
VNDA
Vanda Pharmaceuticals Inc
$6.03
-3.52%
HEALTHCARE · Cap: $366.83M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 25879% more annual revenue ($56.58B vs $217.78M). NVS leads profitability with a 23.9% profit margin vs -110.0%. VNDA appears more attractively valued with a PEG of 2.23. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
VNDA
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+83.7%
Fair Value
$37.46
Current Price
$6.03
$31.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Expensive relative to growth rate
3.4% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : VNDA
The strongest argument for VNDA centers on Price/Book, Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : VNDA
The primary concerns for VNDA are PEG Ratio, Revenue Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while VNDA is a turnaround play — different risk/reward profiles.
VNDA carries more volatility with a beta of 0.60 — expect wider price swings.
VNDA is growing revenue faster at 3.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 37/100), backed by strong 23.9% margins. VNDA offers better value entry with a 83.7% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Vanda Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?